• Biodesix Receives CareFirst BlueCross BlueShield (BCBS) Coverage for VeriStrat Test

    April 21, 2015 Diagnostic deemed medically necessary to guide treatment decisions for patients with advanced non-small cell lung cancer (NSCLC) Biodesix, Inc. today announced that its VeriStrat® test received a positive coverage decision from CareFirst Blue Cross Blue Shield (BCBS).  CareFirst announced its position to extend coverage to the VeriStrat blood-based test for use as “a marker to aid in predicting ... Read more
  • Lung Cancer Journal: VeriStrat Proteomic Test Improves Overall Survival and Decreases Medical Costs for Patients with Advanced NSCLC

    March 24, 2015 Biodesix Inc. today announced the publication in the journal Lung Cancer of a pivotal paper demonstrating the economic implications to the US healthcare system of using VeriStrat® in guiding treatment of patients with advanced non-small cell lung cancer (NSCLC). The paper’s authors conclude that using VeriStrat improves overall survival and decreases medical costs in the ... Read more
  • Biodesix And Inivata To Investigate Clinical Utility Of Next Generation Sequencing-Blood Based Tests For Patients With Advanced Lung Cancer

    March 11, 2015 Biodesix, Inc., a Boulder CO-based molecular diagnostics company, and Inivata, a Cambridge, England-based clinical cancer genomics company announced a partnership today to develop and commercialize Next Generation Sequencing (NGS)-blood based tests for clinical applications in lung cancer.  This agreement will leverage Inivata’s proprietary, enhanced TAm-Seq™ technology platform and Biodesix’ development and commercialization capabilities in the ... Read more
  • Biodesix Raises Additional Series E Financing

    January 12, 2015 Biodesix, Inc., a molecular diagnostics company that develops and commercializes blood-based tests in oncology enabling physicians to make more precise diagnostic and therapeutic decisions, announced today that the company increased the size of its offering of series E preferred shares in a follow-on sale. In addition to the $15 million of series E shares sold ... Read more
  • Biodesix Announces Inclusion of VeriStrat in Updated NCCN Guidelines

    October 27, 2014   Guidelines provide evidence-based, consensus-driven recommendations for managing cancer. Biodesix Inc., a molecular diagnostics company dedicated to advancing precision medicine and improved patient care, today announced that its VeriStrat® blood-based prognostic and predictive proteomics test has been approved for inclusion in the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Non-Small Cell Lung Cancer (NSCLC). NCCN Guidelines ... Read more
  • AVEO and Biodesix Announce Exploratory Analysis of VeriStrat-Selected Patients with Non-Small Cell Lung Cancer in Phase 2 Study of Ficlatuzumab Presented at ESMO 2014 Congress

    September 29, 2014 AVEO Oncology (NASDAQ: AVEO) and Biodesix, Inc. today announced the presentation of results from a retrospective exploratory analysis using VeriStrat®, a commercially available serum protein test, to identify patients most likely to benefit from the addition of ficlatuzumab, AVEO’s HGF inhibitory antibody, to epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitor (TKI) therapy in a randomized ... Read more
  • Biodesix Receives Highmark Blue Cross Blue Shield Coverage for VeriStrat Test

    September 9, 2014 Lung cancer diagnostic deemed medically necessary to guide treatment decisions Biodesix, Inc., a fully integrated molecular diagnostics company dedicated to personalizing medicine, today announced that its VeriStrat® test received a positive coverage decision from Highmark Inc., a Blue Cross Blue Shield (BCBS) affiliate organization and one of the largest insurance companies in the United States. Highmark announced ... Read more
  • Biodesix Announces Publication of Seminal PROSE Study in THE LANCET ONCOLOGY

    May 14, 2014 Study highlights VeriStrat®’s ability to predict differential treatment outcomes between erlotinib and chemotherapy for non-small cell lung cancer Biodesix, Inc., a fully integrated molecular diagnostics company dedicated to personalizing medicine, today announced the publication of results from the investigator-initiated study, “Randomised Proteomic Stratified Phase III Study of Second Line Erlotinib Versus Chemotherapy in Patients with Inoperable ... Read more
  • AVEO and Biodesix Partner to Co-Develop and Commercialize Ficlatuzumab with a Companion Diagnostic for Treatment of NSCLC

    April 10, 2014 Biodesix to Fund Proof of Concept Study  AVEO Oncology (NASDAQ: AVEO) and Biodesix, Inc. today announced that they have entered into a worldwide agreement to develop and commercialize AVEO’s hepatocyte growth factor (HGF) inhibitory antibody ficlatuzumab, with a Biodesix® companion diagnostic test. This agreement and the clinical development program will leverage VeriStrat®, a serum protein test ... Read more
  • Biodesix Receives CE Mark for VeriStrat Specimen Collection and Shipping Kit

    March 3, 2014 Blood-based protein diagnostic predicts differential treatment outcomes for non-small cell lung cancer Biodesix, Inc., a fully integrated molecular diagnostics company dedicated to personalizing medicine, today announced that it has obtained the CE Mark for its VeriStrat® specimen collection and shipping kit, clearing the company to make VeriStrat results available to physicians in the European Union and ... Read more